Abstract
Relevance. According to WHO experts, in the world every year more than 10% of children (about 15 million) are born prematurely. Premature births have a high risk of adverse course of infectious diseases, including vaccine-preventable diseases due to insufficient maternal antibodies, active transmission of which occurs in the third semester of pregnancy. Aim. To study the tolerability of Vactrivir® vaccine in infants born prematurely. Materials and methods. The children (mean age 1.7 ± 0.6 years, born prematurely with a body weight of less than 2500 g) included in the study group participated in the study. The control group consisted of years born at term and comparable in sex and age with the children in the study group. Results. The administration of Vaktrivir® vaccine to infants born prematurely confirmed the high safety profile of the drug. There were no deviations from the norm in general and biochemical blood tests, general urinalysis, and the content of immunoglobulins IgA, IgM, IgG, IgE in the dynamics. There were no undesirable side effects in the postvaccination period, which confirms good tolerability of the drug. Conclusion. In practice, the high safety profile and good tolerability of the domestic tetravaccine Vaktrivir® for immunization of premature infants have been confirmed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
